2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid
• 化学式: C₂₄H₂₂N₂O₅S₂
• 分子量: 482.6
• InChiKey: COFMYJWNXSFLKQ-QIROLCGISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Methods for treating inflammatory bowel disease
  申请人：Nogra Pharma Limited

  公开号：US10473669B2

  公开（公告）日：2019-11-12

  Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.

  公开了用抗SMAD7疗法（如SMAD7反义寡核苷酸）治疗IBD患者以降低CRP水平的方法。还公开了基于CRP水平使用抗SMAD7疗法（如SMAD7反义寡核苷酸）治疗和管理受试者IBD的方法。还公开了确定IBD患者是否对抗SMAD7疗法有反应或可能有反应的方法。CRP水平的降低可能与IBD缓解或CDAI评分的降低相关。本发明还涉及使用抗SMAD7疗法（如反义寡核苷酸）与附加药剂联合治疗IBD。本发明还涉及相关药物组合物和试剂盒。
• Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
  申请人：PROMETHEUS BIOSCIENCES, INC.

  公开号：US11136386B2

  公开（公告）日：2021-10-05

  Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

  本文提供的方法、系统和试剂盒用于根据是否存在与对治疗剂的阳性治疗反应相关的基因型，选择患者接受治疗剂的治疗。在某些实施方案中，治疗剂是 TL1A 活性或表达的抑制剂，例如抗 TL1A 抗体。
• METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE
  申请人：Nogra Pharma Limited

  公开号：EP3140658A2

  公开（公告）日：2017-03-15
• METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES
  申请人：Celgene Alpine Investment Company II, LLC

  公开号：EP3237018A1

  公开（公告）日：2017-11-01
• METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION
  申请人：Nogra Pharma Limited

  公开号：EP3355896A2

  公开（公告）日：2018-08-08